Trastuzumab (or biosimilar)

DRUG5 trials

Sponsors

Fudan University, University of Kansas Medical Center, Tianjin Medical University Cancer Institute and Hospital, Shanghai Jiao Tong University School of Medicine, Hebei Medical University Fourth Hospital

Conditions

Advanced Breast CancerBreast CancerHER2 + Breast CancerHER2-negative Breast CancerMetastatic Breast CancerTriple Negative Breast Cancer (TNBC)

Phase 2

Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer

RecruitingNCT06649331

Fudan UniversityAdvanced Breast Cancer, Breast Cancer, HER2-negative Breast Cancer +2

Start: 2024-10-21End: 2027-09-01Target: 160Updated: 2026-09-03

Trial of Neoadjuvant THP vs TCHP for HER2-Amplified/Positive Breast Cancer

RecruitingNCT07220135

University of Kansas Medical CenterBreast Cancer

Start: 2025-11-14End: 2031-05-14Target: 100Updated: 2026-05-06

Evaluation of Neoadjuvant Therapy With Trastuzumab, Pertuzumab, Docetaxel, and QL1706 in Early or Locally Advanced HER2+ Breast Cancer

Not yet recruitingNCT07246317

Tianjin Medical University Cancer Institute and HospitalBreast Cancer

Start: 2025-12-15End: 2032-12-31Target: 188Updated: 2025-11-28

Neoadjuvant Trastuzumab Deruxtecan (SHR-A1811) + Pertuzumab in HER2+ Breast Cancer

RecruitingNCT07393425

Shanghai Jiao Tong University School of MedicineHER2 + Breast Cancer

Start: 2026-02-02End: 2032-09-30Target: 50Updated: 2026-02-06

Trastuzumab/Pertuzumab With Fulvestrant and Culmerciclib in HR+/HER2+ Early Breast Cancer

Not yet recruitingNCT07857226

Hebei Medical University Fourth HospitalBreast Cancer

Start: 2026-09-01End: 2028-12-01Target: 31Updated: 2026-10-19